A study to access the effect of drug therapyin Recalcitrant Dermatophytosis patients
Not Applicable
- Conditions
- Health Condition 1: B359- Dermatophytosis, unspecified
- Registration Number
- CTRI/2024/05/067543
- Lead Sponsor
- Priti kochar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. All the patients diagnosed with recalcitrant dermatophytosis operational definition of Recalcitrant dermatophytosis refers to relapse,
recurrences, reinfection, persistence or chronic infections, and possibly microbiological resistance.
2. Both male and female with established recalcitrant dermatophytosis.
3. Age 18- 60 years.
Exclusion Criteria
1.Patient diagnosed with other autoimmune dermatological disease like psoriasis.
2. Patient with cutaneous adverse drug reactions.
3. Patient with secondary infected tinea infection
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To analyse the treatment response to antifungals drugs in patients diagnosed with recalcitrant dermatophytosis patients.Timepoint: At baseline and four weeks
- Secondary Outcome Measures
Name Time Method 1. To assess the prescribing pattern of anti-fungal agents and adherence <br/ ><br>to available treatment guidelines. <br/ ><br>2. To evaluate the adverse drug reactions, patient’s adherence to <br/ ><br>treatment and cost of therapy associated with recalcitrant <br/ ><br>dermatophytosis medication. <br/ ><br>3. To assess the effect of antifungal therapy on the quality of life of <br/ ><br>patients. <br/ ><br>4. Subgroup analysis – Comparison of treatment response in patients <br/ ><br>receiving different antifungal agents will be done, if feasible.Timepoint: At baseline and four weeks